You are here

HTX-011

Go or no go? Apellis and Heron head for the finish line

EP Vantage

Fri, 04/30/21 - 10:30 am

Heron Therapeutics

Heron's wings clipped again with another FDA rejection for opioid alternative

Fierce Biotech

Mon, 06/29/20 - 10:02 am

Heron Therapeutics

complete response letter

non-opioid pain treatments

Manufacturing issues hobble Heron’s quest to market its long-acting non-opioid painkiller

Endpoints

Thu, 05/2/19 - 11:05 am

Heron Therapeutics

Pacira Pharmaceuticals

post-surgical pain

Go or no go? Abbvie, Glaxo and Heron await FDA verdicts

EP Vantage

Thu, 03/28/19 - 10:18 am

Heron Therapeutics

dolutegravir/lamivudine

Heron's non-opioid HTX-011 gets Priority Review

BioCentury

Wed, 01/2/19 - 06:49 pm

priority review

Heron Therapeutics

post-operative pain

Heron's HTX-011 for Postoperative Pain Management Receives Breakthrough Therapy Designation from FDA

CP Wire

Thu, 06/21/18 - 09:44 am

Heron Therapeutics

pain management

post-operative pain

Heron's HTX-011 for Postoperative Pain Management Receives Breakthrough Therapy Designation from FDA

Thu, 06/21/18 - 09:17 am

Heron Therapeutics

pain management

3 Biotech Stocks That Skyrocketed This Week

Motley Fool

Sun, 03/25/18 - 11:29 am

Arena Pharmaceuticals

Heron Therapeutics

This Biotech Stock Catapulted After Its Pain Drug Trumped A Key Rival

Investors Business Daily

Tue, 03/20/18 - 09:57 am

Heron Pharmaceuticals

Heron shares surge on positive pain drug data

Fierce Biotech

Wed, 09/23/15 - 09:51 pm

post-operative pain